(Q44849776)

6 December 2017

title

Long-term outcome after intensive therapy with etoposide, melphalan, total body irradiation and autotransplant for acute myeloid leukemia (English)

1 reference

6 December 2017

1 reference

1 reference

Mollee P

1

1 reference

6 December 2017

Gupta V

2

1 reference

6 December 2017

Song K

3

1 reference

6 December 2017

Reddy V

4

1 reference

6 December 2017

Califaretti N

5

1 reference

6 December 2017

Tsang R

6

1 reference

6 December 2017

Crump M

7

1 reference

6 December 2017

Keating A

8

1 reference

6 December 2017

language of work or name

English

0 references

publication date

1 June 2004

1 reference

Bone Marrow Transplantation

6 December 2017

published in

1 reference

6 December 2017

volume

33

1 reference

6 December 2017

issue

12

1 reference

6 December 2017

page(s)

1201-1208

1 reference

Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Par

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704506

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704506

Donor search or autografting in patients with acute leukaemia who lack an HLA-identical sibling? A matched-pair analysis. Acute Leukaemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation (EBMT) and the Internation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704506

Who should be transplanted for AML?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704506

Autologous stem cell transplantation for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704506

Autologous stem cell transplantation for adult acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704506

Immunotherapy with acute leukemia cells modified into antigen-presenting cells: ex vivo culture and gene transfer methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704506

Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704506

A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704506

Autologous bone marrow transplantation for acute myeloid leukemia in remission or first relapse using monoclonal antibody-purged marrow: results of phase II studies with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704506

Autologous stem cell transplantation for advanced acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704506

Transplantation of unpurged autologous bone-marrow in acute myeloid leukaemia in first remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704506

7 January 2021

Autologous bone marrow transplantation following high dose chemotherapy for the treatment of adult patients with acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704506

7 January 2021

Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Ad

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704506

7 January 2021

Impact of cytogenetics on the outcome of autotransplantation for acute myeloid leukemia in first remission: is the benefit of intensive pretransplant therapy limited to patients with good karyotypes?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704506

7 January 2021

The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704506

7 January 2021

High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients with poor clinical outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704506

7 January 2021

Importance of marrow dose on posttransplant outcome in acute leukemia: models derived from patients autografted with mafosfamide-purged marrow at a single institution

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704506

7 January 2021

Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704506

7 January 2021

Autologous bone marrow transplantation in acute myeloid leukemia: the University of Minnesota experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704506

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1704506

1 reference

6 December 2017

1 reference